AiCure

Articles Published in 2011

Metamark, Janssen ink $365 million research agreement

Tuesday, December 20, 2011 01:12 PM

Metamark Genetics has entered into a research, collaboration, and license agreement with Janssen Biotech. The agreement is based on Metamark's discovery platform for the identification and characterization of specific proprietary cancer targets demonstrated to play a causal role in promoting tumor progression and spread. The collaboration will focus on the evaluation and validation of several of Metamark's Prognosis Determinants. Upon selection of the targets, Janssen Biotech will receive a limited exclusive license under Metamark's intellectual property and know-how and will thereafter be responsible for the discovery, development, and commercialization of therapeutic inhibitors targeting the specific Prognosis Determinants.

More... »


Amgen, Watson collaborate to develop oncology biosimiliars

Tuesday, December 20, 2011 12:44 PM

Amgen and Watson Pharmaceuticals will collaborate to develop and commercialize several oncology antibody biosimilar medicines.

More... »


Excelimmune raises $12 million to develop infectious disease programs

Tuesday, December 20, 2011 12:20 PM

Excelimmune has raised $12 million from a private investor. Proceeds will be used by Excelimmune to develop its infectious disease programs, including Staphguard, a human recombinant polyclonal antibody (HRPA) candidate against methicillin-resistant Staphylococcus aureus (MRSA), and to expand its discovery programs to new disease targets beyond infectious diseases through its antibody screening technology.

More... »

ImmunoGen collaborates with Lilly

Tuesday, December 20, 2011 11:02 AM

ImmunoGen has entered into a collaboration agreement with Eli Lilly. Under this agreement, Lilly will pay an upfront fee of $20 million for rights to take a limited number of exclusive licenses to use ImmunoGen's maytansinoid Targeted Antibody Payload (TAP) technology with Lilly monoclonal antibodies to develop novel antibody-drug conjugate (ADC) anticancer therapeutics.

More... »

Access launches initiative to fund early-stage therapeutic companies

Monday, December 19, 2011 02:56 PM

Access Industries has established Access BridgeGap Ventures, a new life sciences venture investment initiative to fund early-stage companies in the therapeutics space. Access BridgeGap will fund early-stage startups and also create de-novo spinoffs around potential high-impact technologies, many of which are still in academic labs.

More... »

Biogen Idec, UCB partner in ALS research

Monday, December 19, 2011 02:39 PM

The ALS Therapy Development Institute (ALS TDI) has formed a research agreement with Biogen Idec and UCB to investigate the use of an anti-CD40L antibody as a potential therapy for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's or Motor Neuron Disease. Financial terms of the agreement were not disclosed.

More... »

Alexza retains Lazard, reduces workforce

Monday, December 19, 2011 01:53 PM

Alexza Pharmaceuticals has retained Lazard to assist in exploring strategic options to enhance stockholder value, including a possible sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions.

More... »

Alkermes initiates phase III ALKS 9070 study for schizophrenia

Monday, December 19, 2011 01:42 PM

Alkermes has initiated a phase III clinical trial of ALKS 9070 for the treatment of schizophrenia. ALKS 9070 is designed to provide patients with once-monthly dosing of a medication that, once in the body, converts into aripiprazole, a molecule that is commercially available under the name ABILIFY for the treatment of a number of central nervous system (CNS) disorders.

More... »

FDA proposes draft guidelines to address underrepresentation of women in clinical studies

Monday, December 19, 2011 12:11 PM
Draft guidance aimed to address the historic underrepresentation of women in clinical studies has been issued by the FDA. Intended for medical device developers and manufacturers, the guidance outlines agency recommendations for designing and conducting device clinical studies that may enhance the enrollment of women in such studies, if appropriate.

More... »

Isis initates phase I spinal muscular atrophy study

Monday, December 19, 2011 11:34 AM

Isis Pharmaceuticals has initiated a phase I study of ISIS-SMNRx in patients with spinal muscular atrophy (SMA).  SMA is a severe motor-neuron disease that is the leading genetic cause of infant mortality. Isis is developing ISIS-SMNRx as a potential treatment for all types of SMA.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 24

Tufts CSDD’s $2.6 billion price tag to develop and bring a new drug to market raises questions, criticisms

Medidata joins GlaxoSmithKline in study to evaluate the impact of wearing mobile devices in clinical trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs